Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Govindarajan Narayanan

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112174539. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2012: 3 papers · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 3 papers

Papers 10

  1. Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results. Co-author DOI 10.1093/oncolo/oyag416↗
  2. pRECIST: Guidelines for Response Criteria for Use in Trials Testing Therapeutics in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002640↗
  3. Irreversible electroporation associated with improved overall survival vs standard of care for stage 3 pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.05.19.26353144↗
  4. Multicenter randomized controlled trial and registry study to assess the safety and efficacy of the NanoKnife® system for the ablation of stage 3 pancreatic ad… Co-author DOI 10.1186/s12885-021-08474-4↗
  5. Ablation in Pancreatic Cancer: Past, Present and Future. Co-author DOI 10.3390/cancers13112511↗
  6. Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.jvir.2016.10.023↗
  7. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1016/j.pan.2015.08.010↗
  8. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. Co-author DOI 10.1016/j.jvir.2012.09.012↗
  9. Interventional radiology and the pancreatic cancer patient. First author DOI 10.1097/ppo.0b013e3182745bee↗
  10. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1186/1471-2407-12-199↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert C.G. Martin · 3 shared papers, 2021–2026 · strength 0.70
  2. Patricio Marcelo Polanco · 2 shared papers, 2026 · strength 0.54
  3. Sean Patrick Cleary · 2 shared papers, 2026 · strength 0.54
  4. Michael D. Kluger · 2 shared papers, 2026 · strength 0.54
  5. Carlos H.F. Chan · 2 shared papers, 2026 · strength 0.54
  6. Chet W. Hammill · 2 shared papers, 2026 · strength 0.54
  7. Rebekah Ruth White · 2 shared papers, 2026 · strength 0.54
  8. Robert C.G. Martin · 1 shared paper, 2026 · strength 0.36
  9. Kohkan Shamsi · 1 shared paper, 2026 · strength 0.36
  10. Peter J. Hosein · 5 shared papers, 2012–2021 · strength 0.31
  11. David A. Iannitti · 1 shared paper, 2026 · strength 0.27
  12. Dania Daye · 1 shared paper, 2021 · strength 0.16
  13. Mehul Doshi · 1 shared paper, 2021 · strength 0.16
  14. Jaime Rafael Merchan · 3 shared papers, 2012–2017 · strength 0.12
  15. Jose M. Yrizarry · 2 shared papers, 2012–2017 · strength 0.09
  16. Caio Rocha‐Lima · 2 shared papers, 2012–2017 · strength 0.09
  17. Caio M. Rocha Lima · 2 shared papers, 2012–2015 · strength 0.07
  18. Daniel B. Brown · 1 shared paper, 2012 · strength 0.06
  19. Jessica MacIntyre · 2 shared papers, 2012–2015 · strength 0.06
  20. Lorraine Portelance · 2 shared papers, 2012–2015 · strength 0.06
  21. Hester J. Scheffer · 1 shared paper, 2017 · strength 0.06
  22. Riccardo Antonio Lencioni · 1 shared paper, 2017 · strength 0.06
  23. Moh'd M. Khushman · 1 shared paper, 2015 · strength 0.04
  24. Ching-Wei David Tzeng · 1 shared paper, 2015 · strength 0.04
  25. Danny Sleeman · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.